

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
06 July 2023 (06.07.2023)



(10) International Publication Number
WO 2023/129667 A1

(51) International Patent Classification:

C07D 241/26 (2006.01) C07D 403/12 (2006.01)
A61K 31/4965 (2006.01) C07D 403/14 (2006.01)
A61K 31/498 (2006.01) C07D 241/20 (2006.01)
A61P 35/00 (2006.01) A61K 31/497 (2006.01)

900 Middlefield Road, 4th Floor, Redwood city, California
94063 (US).

(74) Agent: PATHAK, Rahul et al.; 475 Sansome Street, Suite
1600, Agent, 94111 (US).

(21) International Application Number:

PCT/US2022/054270

(22) International Filing Date:

29 December 2022 (29.12.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/295,494 30 December 2021 (30.12.2021) US
63/316,939 04 March 2022 (04.03.2022) US
63/364,860 17 May 2022 (17.05.2022) US
PCT/US2022/040953

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG,
NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS,
RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI,
SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(71) Applicant: BIOMEA FUSION, INC. [US/US]; 900 Mid-
dlefield Road, 4th Floor, San Francisco, California 94063
(US).

(72) Inventors: SPERANDIO, David; c/o BIOMEA FUSION,
INC., 900 Middlefield Road, 4th Floor, Redwood city, Cal-
ifornia 94063 (US). BUTLER, Thomas; c/o BIOMEA
FUSION, INC., 900 Middlefield Road, 4th Floor, Redwood
city, California 94063 (US). KIRSCHBERG, Thorsten
A.; c/o BIOMEA FUSION, INC., 900 Middlefield Road,
4th Floor, Redwood city, California 94063 (US). WANG,
Xiaodong; c/o BIOMEA FUSION, INC., 900 Middlefield
Road, 4th Floor, Redwood city, California 94063 (US).
LIN, Nan-Hong; c/o BIOMEA FUSION, INC., 900 Mid-
dlefield Road, 4th Floor, Redwood city, California 94063
(US). UNGASHE, Solomon B.; c/o BIOMEA FUSION,
INC., 900 Middlefield Road, 4th Floor, Redwood city, Cal-
ifornia 94063 (US). SQUIRES, Neil Howard; c/o BIOMEA
FUSION, INC., 900 Middlefield Road, 4th Floor, Redwood
city, California 94063 (US). UPASANI, Ravindra B.; c/o
BIOMEA FUSION, INC., 900 Middlefield Road, 4th Floor,
Redwood city, California 94063 (US). PHAN, Thu; c/o
BIOMEA FUSION, INC., 900 Middlefield Road, 4th Floor,
Redwood city, California 94063 (US). PALMER, James
T.; c/o BIOMEA FUSION, INC., 900 Middlefield Road,
4th Floor, Redwood city, California 94063 (US). ADAM,
Amna Trinity-Turjuman; c/o BIOMEA FUSION, INC.,
900 Middlefield Road, 4th Floor, Redwood city, Califor-
nia 94063 (US). SU, Yongli; c/o BIOMEA FUSION, INC.,

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))

(54) Title: PYRAZINE COMPOUNDS AS INHIBITORS OF FLT3

(57) Abstract: Disclosed herein are heterocyclic compounds that inhibit the activity of FLT3. Also described are specific covalent inhibitors of FLT3. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the FLT3 inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of proliferative diseases or conditions, including hematological malignancies and other diseases or conditions dependent on FLT3 activity.



WO 2023/129667 A1